

February 17, 2024

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	--

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

This is to inform that the Company has infused further equity into its wholly-owned subsidiary M/s. Laurus Synthesis Private Limited (LSPL) via subscribing to the rights issue offered by LSPL for a cash consideration of **Rs. 99,13,12,308/-** for acquisition of 7,600 Equity shares of Rs. 10 each at a premium of Rs. 1,30,425.83/- per share.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations read with Section V -A of Chapter V of Master Circular issued vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, is also attached as per 'Annexure'.

This is for your information and record.

Yours faithfully,
For Laurus Labs Limited

G. Venkateswar Reddy
Company Secretary &
Compliance Officer

Annexure

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) name of the target entity, details in brief such as size, turnover etc.;	M/s. Laurus Synthesis Private Limited (LSPL) (Wholly-Owned Subsidiary of M/s. Laurus Labs Limited) Turnover (FY 2022-23) – Rs. 108 Crores
b) whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	Yes. The transaction is a related party as LSPL is a wholly-owned subsidiary of the Company. None of the promoter/ promoter group/ group companies have any interest in LSPL and the transaction is done at arm’s length basis
c) industry to which the entity being acquired belongs;	Pharmaceutical
d) objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company has infused further equity via rights issue keeping in view of the funds requirements of LSPL
e) brief details of any governmental or regulatory approvals required for the acquisition	No
f) indicative time period for completion of the acquisition;	The Company has paid the share application money and 7600 Equity shares of Rs. 10 each were allotted.
g) consideration - whether cash consideration or share swap or any other form and details of the same;	Cash Consideration
h) cost of acquisition and/or the price at which the shares are acquired;	Rs. 99,13,12,308/- for 7,600 equity of shares of Rs. 10 each at a premium of Rs. 1,30,425.83/- per share.
i) percentage of shareholding / control acquired and / or number of shares acquired;	100%
j) brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	M/s. Laurus Synthesis Private Limited, a wholly-owned subsidiary of M/s. Laurus Labs Limited, is a leading Contract Development & Manufacturing Organization (CDMO) with a solid track record in supporting drug development and manufacturing programs of global pharmaceutical and biotech companies. Date of incorporation: May 18, 2020 Last 3 years turnover: FY 2022-23: Rs. 108 Crores FY 2021-22: Rs. 91.20 Crores FY 2020-21: Rs. 15.63 Crores